Story perspectives

Walgreens Settles Opioid Allegations for $350 Million

4/24/2025

25 4

Summary

Story summary

Walgreens will pay up to $350 million to settle DOJ allegations of illegal opioid prescriptions from 2012 to 2023.
The settlement includes a guaranteed $300 million, with an extra $50 million if sold or merged before 2032.
DOJ alleges Walgreens pressured pharmacists to fill prescriptions despite obvious red flags.
Walgreens will improve compliance measures and staff training as part of the agreement.
The company denies wrongdoing but seeks to resolve opioid litigation and refocus on its turnaround strategy.

History

Historical Context

Walgreens' $350 million settlement over opioid prescription allegations reflects a broader crisis rooted in the 1996 launch of OxyContin by Purdue Pharma. Purdue's aggressive marketing downplayed addiction risks, contributing to the opioid epidemic that has claimed over 500,000 lives in the U.S. since 1999. This settlement signals ongoing accountability efforts for pharmacies involved in the crisis, echoing past legal actions against major drug manufacturers.

1 of 2

Story summary

Walgreens will pay up to $350 million to settle DOJ allegations of illegal opioid prescriptions from 2012 to 2023.
The settlement includes a guaranteed $300 million, with an extra $50 million if sold or merged before 2032.
DOJ alleges Walgreens pressured pharmacists to fill prescriptions despite obvious red flags.
Walgreens will improve compliance measures and staff training as part of the agreement.
The company denies wrongdoing but seeks to resolve opioid litigation and refocus on its turnaround strategy.

1 / 2